نتائج البحث - Laurent Detalle

  • يعرض 1 - 4 نتائج من 4
تنقيح النتائج
  1. 1
    Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs

    Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs حسب Alejandro Larios Mora, Laurent Detalle, Jack M. Gallup, Albert Van Geelen, Thomas Stöhr, Linde Duprez, Mark R. Ackermann

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection

    Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection حسب Laurent Detalle, Thomas Stöhr, Concepción Palomo, Pedro A. Piedra, Brian E. Gilbert, Vicente Más, Andrena Millar, Ultan F. Power, Catelijne Stortelers, Koen Allosery, José A. Melero, Erik Depla

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Phase 1/1b Studies of <scp>UCB0599</scp>, an Oral Inhibitor of α‐Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease

    Phase 1/1b Studies of <scp>UCB0599</scp>, an Oral Inhibitor of α‐Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease حسب Johan W. Smit, Peter Basile, Maria Key Prato, Laurent Detalle, François‐Xavier Mathy, Astrid Schmidt, Marianna Lalla, Massimiliano Germani, Coralie Domange, Anja‐Leona Biere, Massimo Bani, Stan Carson, Just Genius

    منشور في 2022
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial

    Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial حسب Steve Cunningham, Pedro A. Piedra, Federico Martinón‐Torres, Henryk Szymański, Benedicte Brackeva, Evelyne Dombrecht, Laurent Detalle, C. Fleurinck, Steve Cunningham, Pedra A Piedra, Stijn Verhulst, Inge Matthijs, Marijke Proesmans, Tessa Goetghebuer, Miroslava Bosheva, S Dosev, Olga Nikolova, Petranka Chakarova, Elba Wu Hupat, Juan Mesa Monsalve, Mirjana Turkalj, Natasa Mesaric Antoncic, Goran Tešović, Mirna Sipl, Blaženka Kljaić Bukvić, Irena Ivković‐Jureković, Biserka Čičak, Sylva Skálová, Gerd Horneff, Christian Vogelberg, E Gács, Krisztina Kalocsai, A. Madarasi, Lajos Kovács, Zoltán Novàk, Zsolt Bene, Shai Ashkenazi, Aviv Goldbart, Lea Bentur, Nadezda Kolosa, Dace Gardovska, Poh Guan Khaw, Teck Hock Toh, Jessie Anne de Bruyne, Kah Kee Tan, Edison Alberto, Junior Sablan Benjamin, Anjanette De Leon, Henryk Szymański, Miroslav Repko, K. Kralinský, Ignacio Salamanca de la Cueva, Carlos Rodrigo, Federico Martinón‐Torres, María Pilar Cedena Romero, Emilio Monteagudo Montesinos, Jamaree Teeratakulpisarn, Thanyawee Puthanakit, Peninnah Oberdorfer, Boonyarat Warachit, Benedicte Brackeva, Evelyne Dombrecht, Laurent Detalle, C. Fleurinck

    منشور في 2020
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: